Recent studies of heterogeneous populations with low bone mass have provided important insights into the pathogenesis of osteoporosis [4]. Thus examining individuals with excess bone mass, identified as a population extreme, is anticipated to be equally informative. We have collected a unique HBM population; having screened 335,115 historical DXA scans across 13 UK National Health Service (NHS) centres for BMD Z/T-scores ≥+ 4. We have previously described the associated clinical characteristics suggestive of a mild skeletal dysplasia in those with unexplained HBM [1]. We recruited a contemporaneous family control population,

comprising unaffected relatives and spouses [1]. click here However, family controls can be expected to be more similar to cases, due to shared SGI-1776 price environmental and inherited factors, than unrelated controls sampled from the general population. Hence, in exploring the phenotype of our HBM cases, additional comparison is needed with unrelated general population controls, with the expectation that the characteristics of family controls lie between those of HBM cases and general population controls. Peripheral

quantitative computed tomography (pQCT) is a low radiation dose research tool enabling measurement of key components of bone geometry which conventional DXA is unable to assess. In the present study, we performed the first systematic evaluation of the skeletal phenotype of HBM individuals sampled from the UK DXA population, assessed using pQCT. In particular, we aimed to establish to what extent alterations in cortical and/or trabecular bone contribute to the increased bone mass observed in HBM, to characterise changes in bone structure underlying these findings, and to determine to what extent altered age-related bone loss contributes to the observed phenotype. The HBM study is a UK based

multi-centred observational study of adults with unexplained HBM. This pQCT study was limited to our largest study centre, where 196 cases of unexplained HBM were identified by screening a NHS GE Lunar DXA database (n = 105,333) (Hull Royal Infirmary). Full details of DXA database screening and participant recruitment have previously been reported [1]. In brief, HBM was defined Clomifene as (a) L1 Z-score of ≥+ 3.2 plus total hip Z-score of ≥+ 1.2 or (b) total hip Z-score ≥+ 3.2 plus L1 Z-score of ≥+ 1.2. Cases with significant osteoarthritis (OA) and/or other causes of raised BMD were excluded (e.g. Paget’s disease, malignancy, artefacts, etc.). L1 was used as it was not associated with the presence of OA, reflecting the recognized pattern of progressive OA changes seen in descending sequential lumbar vertebrae [5]. Index cases were asked to pass on study invitations to their first-degree relatives and spouse/partner(s). Relatives/spouses with HBM were in turn asked to pass on study invitations to their first-degree relatives and spouses.